3Dnamics initial aim has been to engineer 3D organoid models of biological systems and diseases using humans to accelerate the discovery and development of novel therapeutics and medicines for intractable neurological diseases. The quest to find novel therapeutics for neurological disorders has been hindered by the lack of access to relevant samples and experimental models. Currently, roughly 0.1% of drugs that show promise in preclinical testing make it to Phase 1 clinical trials.

Their platform has been successfully applied to model Zika virus-induced microcephaly, toxicity testing, and validation of novel therapeutic compounds for Zika virus infection. In collaboration with the National Institute of Health, 3Dnamics is working towards discovering novel compounds for rare neurological diseases, such as ALS and Frontotemporal Dementia. 

3Dnamics Inc. was founded in 2016 by leading-edge stem cell pioneers and neuroscientists at Johns Hopkins University. 

How MSCRF Helped

3Dnamics was a recipient of the Commercialization Grant through the Maryland Stem Cell Research Fund in 2017.

MSCRF/TEDCO has worked very closely with us to guide the company in the right direction. MSCRF personnel have done a great job of immersing themselves into our field and provided us with key market insights to help the company grow and succeed. Another unique benefit of working with MSCRF is that they have people, Dan and Amritha, who are specialized in stem cell field that truly understands the challenges we are experiencing and can provide the proper mentorship and support.